A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People
← catalyst calendarNCT07797855 · readout in 333 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
112estimated
Sites
1
Country
Netherlands
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-01
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-02 | estimated | When the study began enrolling |
| Primary completion | 2027-08-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-09-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-09-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Cardiometabolic Diseases
Interventions
- Drug: NNC0705-0002
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of treatment emergent adverse events (TEAEs)
measured From time of dosing (day 1) to day 7
Number of TEAEs
measured From time of dosing (day 1) to day 13
AUC0-t, SD; the area under the NNC0705- 0002 plasma concentration-time curve from time 0 to last measurable plasma concentration after a single dose
measured From pre-dose (day 1 or day 10) to day 6 or day 15
Total recovery of administered radiolabelled NNC0705- 0002-related material (sum urine and faeces)
measured From time of dosing (day 1) to no later than day 21
Related
NVO · their whole pipeline · Who in Congress owns NVO?
NVO's other studiesmost recently updated first
- A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood Phase 1 · Completed
- A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation Phase 3 · Active, not recruiting
- A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes Phase 3 · Active, not recruiting
- A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure Phase 1 · Recruiting
- A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity Phase 1 · Recruiting
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed